T1	Participants 58 99	women with locally advanced breast cancer
T2	Participants 415 475	women undergoing neoadjuvant chemotherapy for breast cancer.
T3	Participants 616 831	Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function.
T4	Participants 832 864	120 women were randomly assigned
